SYGNIS AG

euro adhoc: LION bioscience AG
Management Changes
LION bioscience AG expands Management Board after successful acquisition of SYGNIS Bioscience GmbH & Co. KG

@@start.t1@@--------------------------------------------------------------------------------   Disclosure announcement transmitted by euro adhoc.   The issuer is responsible for the content of this announcement. --------------------------------------------------------------------------------@@end@@

09.10.2006

Heidelberg, October 9,  2006  -  After  successful  completion  of the  capital increase in connection with the acquisition of SYGNIS Bioscience GmbH & Co.  KG, the Supervisory Board of LION bioscience AG today appointed Dr. Alfred  Bach  to the Management Board with effect of October 10, 2006. Up to now Dr. Alfred  Bach was CEO of Axaron Bioscience AG, a drug developing company in the field  of  CNS (central nervous  system).  Dr.  Alfred  Bach  will  serve  as  CEO, and  Peter Willinger as CFO of LION bioscience AG. The acquisition of all the shares  in  SYGNIS  Bioscience  GmbH  &  Co.  KG,  as announced in July 2006, was now successfully completed with registration in  the commercial register. Following the acquisition of SYGNIS Bioscience GmbH  &  Co. KG, the share capital of LION bioscience AG  was  increased  by  Euro  7.807.535 from Euro 19.870.175 to Euro 27.677.710. Lion bioscience  AG  will  present the next steps for future  development  on  the  annual shareholders'  meeting  for fiscal year 2005/2006 on November 28, 2006 in Eppelheim.

### Except for the historical information contained herein, the matters  set  forth in this press release are forward looking. These forward-looking statements  may include  projections,  assumptions, estimates,  targets,  and  descriptions  of future events. Such statements are based on currently available information  and on LION's current expectations as to future events that  may  not  prove to  be accurate. These statements are not guarantees of future performance and  involve risks and uncertainties that are difficult to predict. Many factors could  cause the actual results, performance  or  achievements  of  LION  to  be  materially different from those that may be projected,  expected,  targeted,  expressed or implied by such statements. All roll-out plans and future dates with respect  to completion of development and market release of LION products are  target  dates only based on the company's current planning and may change in the  future.  Any delays in the current product release schedule will have  a  materially  adverse effect on the company's targets for fiscal year. ###

@@start.t2@@end of announcement                                                 euro adhoc 09.10.2006 17:31:15
--------------------------------------------------------------------------------@@end@@

ots Originaltext: LION Bioscience AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:
Peter Willinger
Vorstand Finanzen
Telefon: +49(0)6221 4038 293
E-Mail: peter.willinger@lionbioscience.com

Branche: Biotechnology
ISIN:      DE0005043509
WKN:        504350
Index:    CDAX, Prime All Share, Technologie All Share
Börsen:  Frankfurter Wertpapierbörse / regulated dealing/prime
              standard
              New York / ADR
              Börse Berlin-Bremen / free trade
              Hamburger Wertpapierbörse / free trade
              Baden-Württembergische Wertpapierbörse / free trade
              Börse Düsseldorf / free trade
              Niedersächsische Börse zu Hannover / free trade
              Bayerische Börse / free trade



Weitere Meldungen: SYGNIS AG

Das könnte Sie auch interessieren: